{"id":"W4399380532","doi":"10.1200/jco.2024.42.16_suppl.5599","title":"Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Durvalumab; Tolerability; Paclitaxel; Olaparib; Carboplatin; Endometrial cancer; Oncology; Internal medicine; Gynecology; Atezolizumab; Cancer; Urology; Chemotherapy; Cisplatin; Adverse effect; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001053996,0.0004428578,0.000825569,0.0001375599,0.0001592089,0.0005609775,0.0003991724,0.0004947416,0.002128114],"category_scores_gemma":[0.0007352592,0.000234657,0.0006888621,0.0002036424,0.0003205512,0.000375863,0.0001979566,0.001198737,0.0002910666],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006116981,"about_ca_system_score_gemma":0.0004714024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006980494,"about_ca_topic_score_gemma":0.002636799,"domain_scores_codex":[0.9996848,0.0001825035,0.00002052929,0.00004091804,0.00002561623,0.00004562012],"domain_scores_gemma":[0.9997001,0.00006885498,0.00008055544,0.00001967841,0.00001005526,0.0001209021],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8842208,0.007212471,0.0146966,0.0006114053,0.001790687,0.0002112454,0.0001456052,0.001249052,0.01334181,0.0001592122,0.002449935,0.07391117],"study_design_scores_gemma":[0.6368154,0.2915374,0.05809335,0.0001062641,0.00248312,0.000669556,0.0001191947,0.001881679,0.003529219,0.0002879568,0.004434821,0.00004191514],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950596,0.002800466,0.0001428868,0.0001958014,0.00005268316,0.0002693246,0.0004861621,0.00001631488,0.0009768305],"genre_scores_gemma":[0.9970292,0.001024797,0.0002060613,0.0002683174,0.00005376619,0.0001877946,0.0006530908,0.000004666975,0.0005722287],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002128114,"threshold_uncertainty_score":0.007119298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0789982247170708,"score_gpt":0.454991786590238,"score_spread":0.3759935618731672,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}